Skip to main content

September 2018

 

Clinical courses

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for the gene therapy Luxturna (voretigene neparvovec), for the treatment of adults and children suffering from inherited retinal dystrophy caused by RPE65 gene mutations, a rare genetic disorder which causes vision loss and usually leads to blindness.

Americans depend on the U.S. Food and Drug Administration to help ensure that the foods they buy and consume are safe.

Our teams routinely work with food producers on voluntary recalls, and when necessary and where applicable, mandate recalls in order to keep people from getting sick or being harmed. To promote these goals, FDA is  advancing an important new policy.

Job for M.Pharm, M.Sc in Health and Disease research at IISER

Indian Institute of Science Education and Research Pune is a premier autonomous Institution established by the Ministry of Human Resource Development, Government of India, for promotion of high quality science education and research in the country.

Institute invites applications from Indian nationals having excellent academic record and relevant work experience for the following positions purely on temporary and contractual basis under the funded project:

Walk in interview for Pharmacist, Assistant Pharmacist at MCC - under Health and Family Welfare Department

Malabar Cancer Centre is an autonomous institution under Health and Family Welfare Department, Government of Kerala registered under Societies Registration Act XXI of 1860, with an aim to establish a hospital, providing the much-required oncology care to the population of North Kerala. The main objective being establishing a modern Cancer Hospital and Research and Training Centre of international standard in treatment and prevention of cancer.

Vacancy for Ph.D, M.Pharm, M.Sc as Scientist at Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace innovation—bringing ideas, products and services to life to advance the health and well-being of people around the world. We believe in collaboration, and that has led to breakthrough after breakthrough, from medical miracles that have changed lives, to the simple consumer products that make every day a little better. Our over 125,000 employees in 60 countries are united in a common mission: To help people everywhere live longer, healthier, happier lives.

Post : Scientist

Walk in interview for the post of Young Prefessional at CIRB

Central Institute for Research on Buffaloes (CIRB) was established in the year 1985 and started functioning from 1 February, 1985. A sub-campus was later added in December,1987 at Bir Dosanjh, Nabha, District Patiala, Punjab. A highly pedigreed breeding herd of Murrah is established at main campus in Hisar and that of Nili-Ravi buffaloes at sub-campus Nabha. The institute carries out research on various aspects of buffalo improvement including conservation, improvement and propagation of germplasm, development of optimum rations and feeding systems for different categories of buffaloes, enhancement of reproductive efficiency, health management practices for augmenting milk, meat and draught performance of the species.

Walk in interview for Junior Research Fellow at IVRI

Established in 1889, the Indian Veterinary Research Institute (IVRI) is one of the premier research institutions dedicated to livestock research and development of the region. The institute with faculty strength of more than 275 has a major mandate of research, teaching, consultancy and technology transfer activities. The institute with its long scientific heritage has always enjoyed a certain prestige, a tradition all of its own. The institute imparts quality post-graduate education to students not only from various parts of the country, but also from overseas.

Post : Junior Research Fellow

Work as MQ TS Downstream Senior Specialist at Pfizer

Pfizer is the world's premier biopharmaceutical company taking new approaches to better health.  We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.

Post : MQ TS Downstream Senior Specialist

(adsbygoogle = window.adsbygoogle || []).push({});
Work as Medical Science Liaison at IQVIA

Quintiles and IMS Health have come together to become IQVIA, The Human Data Science Company™. Inspired by the industry we help, IQVIA commits to providing solutions that enable life sciences companies to innovate with confidence, maximize their opportunities and ultimately drive human health outcomes forward.

Post : Medical Science Liaison

The U.S. Food and Drug Administration  announced that it has awarded 12 new clinical trial research grants totaling more than USD18 million over the next four years to enhance the development of medical products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country.
The FDA awarded the grants through the Orphan Products Clinical Trials Grants Program.

This program is funded by Congressional appropriations and encourages clinical development of drugs, biologics, medical devices or medical foods for use in rare diseases. The grants are intended for clinical studies evaluating the safety and effectiveness of products that could either result in, or substantially contribute to, the FDA approval of products targeted to the treatment of rare diseases. Grant applications were reviewed and evaluated for scientific and technical merit by more than 100 rare disease experts, which included representatives from academia, the National Institutes of Health and the FDA.

The grant recipients, principal investigators and approximate funding amounts, listed alphabetically, are: Alkeus Pharmaceuticals, Inc. (Cambridge, Massachusetts), Leonide Saad, phase 2 study of ALK-001 for the treatment of Stargardt disease – USD1.75 million over four years; Arizona State University-Tempe Campus (Tempe, Arizona), Keith Lindor, phase 2 study of oral vancomycin for the treatment of primary sclerosing cholangitis – USD2 million over four years; Cedars-Sinai Medical Center (Los Angeles), Shlomo Melmed, phase 2 study of seliciclib for the treatment of Cushing disease – USD2 million over four years; Columbia University of New York (New York), Yvonne Saenger, phase 1 study of talimogene laherparepvec for the treatment for advanced pancreatic cancer –  USD750,000 over three years; Emory University (Atlanta), Eric Sorscher, phase 1/ 2 study of Ad/PNP fludarabine for the treatment of head and neck squamous cell carcinoma – USD1.5 million over three years.

Fibrocell Technologies, Inc. (Exton, Pennsylvania), John Maslowski, phase 1/2 study of gene-modified ex-vivo autologous fibroblasts for the treatment of dystrophic epidermolysis bullosa – USD1.5 million over four years; Johns Hopkins University (Baltimore), Amy Dezern, phase 1/2 study of CD8-reduced T cells for the treatment of myelodysplastic syndrome or acute myeloid leukemia – USD750,000 over three years; Oncolmmune, Inc. (Rockville, Maryland) Yang Liu, phase 2b study of CD24Fc for the prevention of graft versus host disease – USD2 million over four years; Patagonia Pharmaceuticals, LLC (Woodcliff Lake, New Jersey), Zachary Rome, phase 2 study of PAT-001 (isotretinoin) for the treatment of congenital ichthyosis – USD1.5 million over three years; The General Hospital Corporation (Boston), Stephanie Seminara, phase 2 study of kisspeptin for the treatment of dopamine agonist intolerant hyperprolactinemia – USD1.4 million over four years; University of Minnesota (Minneapolis), Kyriakie Sarafoglou, phase 2a study of subcutaneous hydrocortisone infusion pump for the treatment of congenital adrenal hyperplasia – USD1.4 million over three years; University of North Carolina at Chapel Hill (Chapel Hill, North Carolina), Matthew Laughon, phase 2 study of sildenafil for the prevention of bronchopulmonary dysplasia – USD2 million over four years


One-third (33 percent) of the new awards aim to accelerate cancer research by enrolling patients with rare forms of cancer, including advanced pancreatic cancer, head and neck squamous cell carcinoma, myelodysplastic syndrome and acute myeloid leukemia. Another 25 percent of the new awards fund studies evaluating drug products for rare endocrine disorders, including Cushing disease, dopamine agonist intolerant hyperprolactinemia and congenital adrenal hyperplasia. Another study addresses an unmet need in primary sclerosing cholangitis, a rare, chronic and potentially serious bile duct disease.

About 42 percent of the grants fund studies which enroll children and adolescents, targeting a variety of rare diseases in children such as Stargardt disease, a juvenile genetic eye disorder that causes progressive vision loss; dystrophic epidermolysis bullosa, a genetic condition that causes the skin to be fragile resulting in painful blisters; and bronchopulmonary dysplasia, a serious lung condition that affects infants.


To date, the program’s grants have supported research that led to the marketing approval of more than 60 orphan products. Among the recent product approvals which were supported by studies funded by this grants program are a marketing approval for a much-needed treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with multidrug resistant HIV-1 infection and another approval to reduce the acute complications of sickle cell disease in adult and pediatric patients.

The FDA is also currently supporting six natural history studies for rare diseases to further advance the mission of bringing new therapies to market.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email